Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Manuel A. Ferrandiz"'
Autor:
Manuel A. Ferrandiz, Pierre Quartier, Enrique Faugier, Nicolino Ruperto, R. Wong, Julie Passarell, Clovis A. Silva, Graciela Espada, Ingrid Louw, Alberto Martini, Valeria Gerloni, Linda Wagner-Weiner, Gabriel Vega-Cornejo, Marleen Nys, Jason Dare, Yash Gandhi, Hermine I. Brunner, Daniel J. Lovell, Rolando Cimaz, Nikolay Tzaribachev
Publikováno v:
The Journal of Rheumatology. 48:1073-1081
Objective.To assess the relationship between infection risk and abatacept (ABA) exposure levels in patients with polyarticular-course juvenile idiopathic arthritis (pJIA) following treatment with subcutaneous (SC) and intravenous (IV) ABA.Methods.Dat
Autor:
David M. Roth, Deborah M. Levy, Michael Henrickson, Inmaculada Calvo Penades, Carlos Abud-Mendoza, Michael Shishov, Vyacheslav Chasnyk, Julia E Calderon, Antonio Nino, Diego O Viola, Alina Boteanu, Manuel A. Ferrandiz, Maria Gastanaga, Herbert Struemper, Mei-Lun Wang, Anne E. Hammer, Kenneth L. Clark, Hermine I. Brunner, Beulah Ji, Vladimir Keltsev, Nicolino Ruperto, Daniel J. Lovell, Jordi Anton, Damon Bass, Alberto Martini
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThis ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE).MethodsPatients (5 to 17 years) wer
Autor:
Damon Bass, Hermine I. Brunner, Herbert Struemper, Daniel J. Lovell, Anne E. Hammer, Antonio Nino, Michael Shishov, Mei-Lun Wang, Beulah Ji, Kenneth L. Clark, Vladimir Keltsev, Julia Calderon Gallegos, Alberto Martini, Vyacheslav Chasnyk, Jordi Anton, David M. Roth, Manuel A. Ferrandiz, Alina Boteanu, Carlos Abud-Mendoza, Inmaculada Calvo, Maria Gastanaga, Deborah M. Levy, Nicolino Ruperto, Diego O Viola, Michael Henrickson
Publikováno v:
Poster Presentations.
Background: Belimumab (BEL), a monoclonal antibody targeting the B-lymphocyte stimulator, is approved in adults with active systemic lupus erythematosus (SLE). This is the first clinical trial of belimumab in pediatric patients with childhood-onset S
Autor:
Gergely Bodon, Jean-Claude Dosch, J. L. Dietemann, Stephan Gaillard, S. Bennis, S. Aldea, E. Mireau, B. Baussart, M. Dupuy, Claes Olerud, Philippe Bancel, Bernhard Jeanneret, Juan Antonio Martín-Benlloch, José Manuel Casamitjana Ferrandiz, Carlos Villas, Christian Mazel, L. Balabaud, David Choi, O. Doerr, J. Degreif, Isador H. Lieberman, Jean-Marc Vital, I. Obeid, A. Bourghli, O. Gille, Yann Philippe Charles, S. Schuller, A. Walter, Paul F. Heini, L. Benneker, Samo K. Fokter, Fabrice Parker, Lluis Aguilar, Jean-Paul Steib, Jérôme Allain, Ch. Flouzat Lachaniette, A. Poignard, Enric Càceres, L. Lima, S. Persohn, P. Rouch, W. Skalli
Publikováno v:
ArgoSpine News & Journal. 24:9-38
Autor:
M.L. Gamir, Sara Marchesan Oliveira, NM Wulffraat, N Ruperto, Hermine I. Brunner, Karine Lheritier, R. Cimaz, Daniel J. Lovell, Corine Gaillez, K. Nistala, A Martini, Yosef Uziel, Manuel A. Ferrandiz, Ken Abrams, Berit Flatø, I Kone-Paut
Publikováno v:
Annals of the Rheumatic Diseases. 73:130.2-130
Background Systemic juvenile idiopathic arthritis (SJIA) is characterized by recurrent flares of active disease comprising of fever, arthritis and markedly elevated inflammatory markers. Canakinumab (CAN), a fully human, selective, anti-IL-1β monocl
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S13-S14
Autor:
Tilmann Kallinich, Karine Lheritier, Riva Brik, H. Ozdogan, Liza J McCann, Manuel A. Ferrandiz, A. Gnanasakthy, NM Wulffraat, Dennis Y. Kim, Lidia Rutkowska-Sak
Publikováno v:
Annals of the Rheumatic Diseases. 71:266.3-267
Background Patient’s quality of life is markedly affected by the persistent and disabling disease features of systemic juvenile idiopathic arthritis (SJIA). We evaluated the direct impact of the disease on patients’ well being and the improvement
Autor:
Stefania Viola, I Kone-Paut, Bo Magnusson, Michael Hofer, N Ruperto, Inmaculada Calvo, K. Nistala, R. Schneider, Dennis Y. Kim, M. Luz Gamir, Seza Ozen, Daniel J. Lovell, Pierre Quartier, A Martini, Carine Wouters, Tilmann Kallinich, Muferet Erguven, Laurence Goffin, Yosef Uziel, A. Grom, Flavio Sztajnbok, Manuel A. Ferrandiz, Lidia Rutkowska-Sak, Karine Lheritier, NM Wulffraat, S. Knupp, Berit Flatø, G. Horneff, Tamás Constantin, Ozgur Kasapcopur, Ken Abrams, R. Cimaz, Hermine I. Brunner, Riva Brik, Yackov Berkun, Liza J McCann
Publikováno v:
Annals of the Rheumatic Diseases. 71:705.9-705
Background Systemic juvenile idiopathic arthritis (SJIA) is an IL1β-mediated autoinflammatory disease, characterized by spiking intermittent fever, rash, and arthritis. Canakinumab (CAN), a selective, fully human, anti-IL1β monoclonal antibody has
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S14
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S13